AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1753042 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural hypotension assessment at 3 minutes after standing
Number of subjects: 4736
Study 1753042 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural hypotension assessment at both time intervals (1 and 3 minutes)
Number of subjects: 4736
Study 1753042 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural hypotension assessment at either or both time intervals
Number of subjects: 4736
Study 7020438 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized hypnotherapy (six brief sessions)
Number of subjects: 0
Study 30853020 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Preconditioning (RIP)
Number of subjects: 80
Study 30853020 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 80
Study 27932571 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol, 1 mg/kg before aortic cross‐clamping and 2 mg/kg with Custodiol® crystalloid cardioplegia
Number of subjects: 0
Study 27932571 — intervention group
Group type: COMPARATOR
Intervention: Placebo (equivolume)
Number of subjects: 0
Study 27932571 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 0
Study 27932571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26086920 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 682
Study 26086920 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg IVTA
Number of subjects: 682
Study 26086920 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg IVTA
Number of subjects: 682
Study 24798072 — intervention group
Group type: EXPERIMENTAL
Intervention: eSET plus single-embryo cryotransfer
Number of subjects: 194
Study 24798072 — intervention group
Group type: COMPARATOR
Intervention: Double embryo transfer (DET)
Number of subjects: 194
Study 22952293 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 835
Study 22952293 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical bacillus Calmette‐Guérin therapy
Number of subjects: 835
Study 19571639 — intervention group
Group type: EXPERIMENTAL
Intervention: Restless legs syndrome patients
Number of subjects: 36
Study 19571639 — intervention group
Group type: COMPARATOR
Intervention: Normal group
Number of subjects: 36
Study 17293637 — intervention group
Group type: EXPERIMENTAL
Intervention: Low polyphenolic content beverage (LPC)
Number of subjects: 20
Study 17293637 — intervention group
Group type: EXPERIMENTAL
Intervention: High polyphenolic content beverage (HPC)
Number of subjects: 20
Study 17293637 — intervention group
Group type: COMPARATOR
Intervention: Comparison between LPC and HPC
Number of subjects: 20
Study 15125467 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-2 (0.5 pmol kg body wt(‐1) min(‐1))
Number of subjects: 8
Study 15125467 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-2 (1.0 pmol kg body wt(‐1) min(‐1))
Number of subjects: 8
Study 15125467 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 (0.5 pmol kg body wt(‐1) min(‐1))
Number of subjects: 8
Study 15125467 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 and GLP-2 (0.5 pmol kg body wt(‐1) min(‐1))
Number of subjects: 8
Study 15125467 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 8
Study 16978305 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (50 microg) with levobupivacaine
Number of subjects: 0
Study 16978305 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (150 microg) with levobupivacaine
Number of subjects: 0
Study 16978305 — intervention group
Group type: COMPARATOR
Intervention: Levobupivacaine (0.25%) plus saline (control group)
Number of subjects: 0
Study 16978305 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia without paravertebral analgesia (control group)
Number of subjects: 0
Study 10392863 — intervention group
Group type: EXPERIMENTAL
Intervention: Directional atherectomy (CMS system)
Number of subjects: 986
Study 10392863 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty (CMS system)
Number of subjects: 986
Study 10392863 — intervention group
Group type: EXPERIMENTAL
Intervention: Directional atherectomy (ARTREK system)
Number of subjects: 986
Study 10392863 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty (ARTREK system)
Number of subjects: 986
Study 10392863 — intervention group
Group type: EXPERIMENTAL
Intervention: CMS system
Number of subjects: 986
Study 10392863 — intervention group
Group type: EXPERIMENTAL
Intervention: ARTREK system
Number of subjects: 986
Study 8895262 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 150 micrograms/kg up to a maximum dose of 8 mg, administered IV before surgery
Number of subjects: 133
Study 8895262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 2049258 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg daily
Number of subjects: 21
Study 2049258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 6395464 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin 150 mg/kg/day for 7.2 ± 2.75 days
Number of subjects: 41
Study 6395464 — intervention group
Group type: COMPARATOR
Intervention: Carbenicillin 200 mg/kg/day for 7.5 ± 2.90 days
Number of subjects: 41
Study 30621613 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacunar infarction of SAI
Number of subjects: 834
Study 30621613 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-lacunar infarction of SAI
Number of subjects: 834
Study 30621613 — intervention group
Group type: COMPARATOR
Intervention: MAIs
Number of subjects: 834
Study 27907845 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased maternal childhood adversities
Number of subjects: 1974
Study 27907845 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher household wealth
Number of subjects: 1974
Study 27907845 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal education
Number of subjects: 1974
Study 27907845 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support, reporting HIV+, school enrollment of biologically-related children, overall health, reported alcohol use, and functional literacy
Number of subjects: 1974
Study 27117972 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutonix drug-coated balloon (DCB)
Number of subjects: 126
Study 27117972 — intervention group
Group type: COMPARATOR
Intervention: Uncoated balloon (PTA)
Number of subjects: 126
Study 25148950 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy (application of ice packs for 30 min)
Number of subjects: 60
Study 25148950 — intervention group
Group type: EXPERIMENTAL
Intervention: Short‐wave diathermy (for 20 min)
Number of subjects: 60
Study 25148950 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 21788917 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular coiling
Number of subjects: 413
Study 21788917 — intervention group
Group type: COMPARATOR
Intervention: Neurosurgical clipping
Number of subjects: 413
Study 21788917 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater clot clearance
Number of subjects: 413
Study 21788917 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline Hijdra score
Number of subjects: 413
Study 19539078 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin 10/20 mg
Number of subjects: 1128
Study 19539078 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin 10/40 mg
Number of subjects: 1128
Study 19539078 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin
Number of subjects: 1128
Study 19539078 — intervention group
Group type: COMPARATOR
Intervention: ezetimibe/simvastatin and atorvastatin
Number of subjects: 1128
Study 16540080 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual cognitive behaviour therapy (CBT) for 10 weeks
Number of subjects: 0
Study 16540080 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive behaviour therapy (CBT) for 10 weeks
Number of subjects: 0
Study 16540080 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control for 10 weeks
Number of subjects: 0
Study 15152132 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol (100 mg twice daily)
Number of subjects: 705
Study 15152132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 705
Study 12010934 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic agents (Class IA)
Number of subjects: 91
Study 12010934 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic agents (Class IC)
Number of subjects: 91
Study 12010934 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic agents (Class III)
Number of subjects: 91
Study 12010934 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 12010934 — intervention group
Group type: EXPERIMENTAL
Intervention: All drug classes
Number of subjects: 91
Study 9577502 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-dimensional MR digital subtraction angiography
Number of subjects: 23
Study 9577502 — intervention group
Group type: COMPARATOR
Intervention: Two-dimensional time-of-flight (TOF) MR angiography
Number of subjects: 23
Study 7641048 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical sodium hyaluronate
Number of subjects: 40
Study 7641048 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Healon buffer)
Number of subjects: 40
Study 30608463 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA patch
Number of subjects: 154
Study 30608463 — intervention group
Group type: EXPERIMENTAL
Intervention: TDP patch
Number of subjects: 154
Study 30608463 — intervention group
Group type: COMPARATOR
Intervention: Lubricant gel patch (control)
Number of subjects: 154
Study 29195623 — intervention group
Group type: EXPERIMENTAL
Intervention: Informative self-disclosure
Number of subjects: 338
Study 29195623 — intervention group
Group type: EXPERIMENTAL
Intervention: Apologetic self-disclosure
Number of subjects: 338
Study 29195623 — intervention group
Group type: COMPARATOR
Intervention: No self-disclosure
Number of subjects: 338
Study 26165012 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild OSAHS Montelukast Treatment (MM) group - treated with leukotriene receptor antagonists (LTRAs)
Number of subjects: 118
Study 26165012 — intervention group
Group type: COMPARATOR
Intervention: Mild OSAHS Adenotonsillectomy Treatment (MAT) group - treated with adenotonsillectomy
Number of subjects: 118
Study 26165012 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild OSAHS Montelukast Treatment (MM) group
Number of subjects: 118
Study 26165012 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe OSAHS Montelukast Treatment (SM) group - treated with LTRAs
Number of subjects: 118
Study 26165012 — intervention group
Group type: COMPARATOR
Intervention: Severe OSAHS Adenotonsillectomy Treatment (SAT) group - treated with adenotonsillectomy
Number of subjects: 118
Study 26165012 — intervention group
Group type: COMPARATOR
Intervention: Mild OSAHS Adenotonsillectomy Treatment (MAT) group
Number of subjects: 118
Study 26165012 — intervention group
Group type: COMPARATOR
Intervention: Severe OSAHS Adenotonsillectomy Treatment (SAT) group
Number of subjects: 118
Study 26165012 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe OSAHS Montelukast Treatment (SM) group
Number of subjects: 118
Study 23210546 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message follow-up showing concern and reassurance
Number of subjects: 39
Study 23210546 — intervention group
Group type: COMPARATOR
Intervention: Control group (no postprocedural communication)
Number of subjects: 39
Study 23210546 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 39
Study 21463707 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face delivered exercise group (FtF)
Number of subjects: 200
Study 21463707 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone delivered exercise group (Tel)
Number of subjects: 200
Study 21463707 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (UC)
Number of subjects: 200
Study 19690991 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytology + /HPV + (Group A, n=58)
Number of subjects: 197
Study 19690991 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytology-/HPV + (Group B, n=41)
Number of subjects: 197
Study 19690991 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytology + /HPV- (Group C, n=9)
Number of subjects: 197
Study 19690991 — intervention group
Group type: COMPARATOR
Intervention: Cytology-/HPV- (Group D, n=89)
Number of subjects: 197
Study 16971641 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium lactis Bb12 supplementation
Number of subjects: 69
Study 16971641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 12652333 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral subcutaneous hand injection of polyclonal human immunoglobulin G (HIgG) labelled with technetium‐99m
Number of subjects: 37
Study 12652333 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral subcutaneous hand injection of polyclonal human immunoglobulin G (HIgG) labelled with indium‐111
Number of subjects: 37
Study 11164063 — intervention group
Group type: EXPERIMENTAL
Intervention: CFS patients
Number of subjects: 277
Study 11164063 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 277
Study 9352953 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and either mitomycin C and doxorubicin
Number of subjects: 0
Study 9352953 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin combination
Number of subjects: 0
Study 7506171 — intervention group
Group type: EXPERIMENTAL
Intervention: nimesulide (100mg twice daily)
Number of subjects: 60
Study 7506171 — intervention group
Group type: COMPARATOR
Intervention: diclofenac (50 mg/kg twice daily)
Number of subjects: 60
Study 3548627 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (2.4 g as a single intravenous dose)
Number of subjects: 94
Study 3548627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 3548627 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 94
Study 31977840 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-tailored smoking cessation intervention
Number of subjects: 229
Study 31977840 — intervention group
Group type: COMPARATOR
Intervention: Attention-controlled intervention
Number of subjects: 229
Study 29198583 — intervention group
Group type: EXPERIMENTAL
Intervention: Closure (C) of the donor site
Number of subjects: 135
Study 29198583 — intervention group
Group type: COMPARATOR
Intervention: Nonclosure (NC) of the donor site
Number of subjects: 135
Study 27311846 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg flurbiprofen
Number of subjects: 90
Study 27311846 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg diclofenac sodium
Number of subjects: 90
Study 27311846 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg tenoxicam
Number of subjects: 90
Study 27311846 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 90
Study 25297618 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme-treated asparagus extract (ETAS)
Number of subjects: 2
Study 25297618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 22365481 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based intensive exercise program supervised by a physical therapist
Number of subjects: 30
Study 22365481 — intervention group
Group type: COMPARATOR
Intervention: Usual care consisting of 1 session of instructions
Number of subjects: 30
Study 20467920 — intervention group
Group type: EXPERIMENTAL
Intervention: MP plus thalidomide
Number of subjects: 0
Study 20467920 — intervention group
Group type: EXPERIMENTAL
Intervention: MP plus bortezomib
Number of subjects: 0
Study 20467920 — intervention group
Group type: EXPERIMENTAL
Intervention: lenalidomide plus MP
Number of subjects: 0
Study 20467920 — intervention group
Group type: EXPERIMENTAL
Intervention: lenalidomide plus dexamethasone
Number of subjects: 0
Study 20467920 — intervention group
Group type: EXPERIMENTAL
Intervention: high-dose dexamethasone plus thalidomide
Number of subjects: 0
Study 20467920 — intervention group
Group type: EXPERIMENTAL
Intervention: high-dose dexamethasone plus lenalidomide (RD)
Number of subjects: 0
Study 20467920 — intervention group
Group type: EXPERIMENTAL
Intervention: high-dose dexamethasone plus bortezomib (VD)
Number of subjects: 0
Study 20467920 — intervention group
Group type: EXPERIMENTAL
Intervention: bortezomib plus pegylated-liposomal-doxorubicin
Number of subjects: 0
Study 20467920 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive care
Number of subjects: 0
Study 19402836 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 1006
Study 15941887 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme-hydrolyzed casein (EHC; MW <5000)
Number of subjects: 8
Study 15941887 — intervention group
Group type: COMPARATOR
Intervention: Protein-free diet
Number of subjects: 8
Study 12749573 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Motivational Interviewing (BMI) training
Number of subjects: 22
Study 12749573 — intervention group
Group type: COMPARATOR
Intervention: Untrained group (Control)
Number of subjects: 22
Study 10333163 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 877
Study 10333163 — intervention group
Group type: COMPARATOR
Intervention: Moclobemide
Number of subjects: 877
Study 8541438 — intervention group
Group type: EXPERIMENTAL
Intervention: Methohexital
Number of subjects: 40
Study 8541438 — intervention group
Group type: COMPARATOR
Intervention: Thiopental
Number of subjects: 40
Study 1682543 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 586
Study 1682543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 586
Study 7328226 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental treatment group
Number of subjects: 70
Study 7328226 — intervention group
Group type: COMPARATOR
Intervention: Placebo control group
Number of subjects: 70
Study 7328226 — intervention group
Group type: COMPARATOR
Intervention: Low-risk 'normal' control group
Number of subjects: 70
Study 31541539 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 29126290 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine (LT4) treatment
Number of subjects: 366
Study 29126290 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 366
Study 26988766 — intervention group
Group type: EXPERIMENTAL
Intervention: Postexercise test (EXER) after standardized breakfast, endurance exercise, and 2 h fasting recovery
Number of subjects: 13
Study 26988766 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting test (FAST) 12 h after a standardized evening meal
Number of subjects: 13
Study 26988766 — intervention group
Group type: COMPARATOR
Intervention: Control test (CON) performed 3 h after a standardized breakfast
Number of subjects: 13
Study 26988766 — intervention group
Group type: EXPERIMENTAL
Intervention: EXER compared to FAST
Number of subjects: 13
Study 26988766 — intervention group
Group type: COMPARATOR
Intervention: FAST compared to CON
Number of subjects: 13
Study 26988766 — intervention group
Group type: COMPARATOR
Intervention: Blood insulin levels at the start of EXER compared with CON and FAST
Number of subjects: 13
Study 26988766 — intervention group
Group type: COMPARATOR
Intervention: Free fatty acid and cortisol levels at the start of EXER compared with CON and FAST
Number of subjects: 13
Study 23148449 — intervention group
Group type: COMPARATOR
Intervention: Increasing price trend
Number of subjects: 30
Study 23148449 — intervention group
Group type: COMPARATOR
Intervention: Decreasing price trend
Number of subjects: 30
Study 22980723 — intervention group
Group type: EXPERIMENTAL
Intervention: Biaxial small-incision torsional phacoemulsification
Number of subjects: 70
Study 22980723 — intervention group
Group type: COMPARATOR
Intervention: Biaxial small-incision longitudinal phacoemulsification
Number of subjects: 70
Study 20345390 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa (target hemoglobin 9.5-11.0 g/dL and 11.5-13.0 g/dL)
Number of subjects: 118
Study 20345390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 17030095 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain-reducing ointment (placebo)
Number of subjects: 96
Study 17030095 — intervention group
Group type: COMPARATOR
Intervention: Neutral ointment (control)
Number of subjects: 96
Study 15980714 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mm intracoronal barrier of Triage glass ionomer
Number of subjects: 30
Study 15980714 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mm Triage barrier
Number of subjects: 30
Study 15980714 — intervention group
Group type: COMPARATOR
Intervention: No barrier (Control)
Number of subjects: 30
Study 11838886 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination low-fat/low-energy diet
Number of subjects: 86
Study 11838886 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 86
Study 11838886 — intervention group
Group type: COMPARATOR
Intervention: Low-energy diet
Number of subjects: 86
Study 10404809 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal E2 (300 microg/day)
Number of subjects: 420
Study 10404809 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal E2 (100, 200, 300, and 400 microg/day)
Number of subjects: 420
Study 10404809 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral E2 (1 and 2 mg/day)
Number of subjects: 420
Study 10404809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 420
Study 7579507 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic random sampling (SRS) with 50 nuclei (SRS-50)
Number of subjects: 191
Study 7579507 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic random sampling (SRS) with 100 nuclei (SRS-100)
Number of subjects: 191
Study 7579507 — intervention group
Group type: COMPARATOR
Intervention: At convenience sampling (ACS) with 50 nuclei (ACS-50)
Number of subjects: 191
Study 2404636 — intervention group
Group type: COMPARATOR
Intervention: Verapamil (120 mg t.i.d.)
Number of subjects: 66
Study 2404636 — intervention group
Group type: COMPARATOR
Intervention: Nicardipine (30 mg t.i.d.)
Number of subjects: 66
Study 2404636 — intervention group
Group type: COMPARATOR
Intervention: Nisoldipine (10 mg b.i.d.)
Number of subjects: 66
Study 2404636 — intervention group
Group type: COMPARATOR
Intervention: Nisoldipine and digoxin (in congestive heart failure)
Number of subjects: 66